Farmakoterapia w niealkoholowej stłuszczeniowej chorobie wątroby

• Autorzy: Kolakowski M. , Kukla M. , Jarosz M.

Warianty tytułu

EN

Farmacotherapy of nonalcoholic fatty liver disease

• Języki publikacji: PL

Abstrakty

PL

Niealkoholowa stłuszezeniowa choroba wątroby (nonalcoholic fatty liver disease, NAFLD) jest stanem obejmującym szerokie spektrum zmian patofizjologicznych - od stłuszczenia prostego (simple fatty liver - SFL), poprzez niealkoholowe stłuszczeniowe zapalenie (steatohepatitis - NASH), po stłuszczeniową marskość wątroby z jej potencjalnymi powikłaniami, w tym rakiem wątrobowo-komórkowym. Choć pojęcie niealkoholowej stłuszczeniowej choroby wątroby obecne było w literaturze medycznej od ponad 30 lat, to przez większość tego czasu traktowane było jako zaburzenie łagodne, bez większego znaczenia klinicznego. Dopiero ostatnie lata, wraz z rosnącą liczbą opracowań analizujących długofalowe konsekwencje zdrowotne NAFLD, zmieniły to podejście i, co za tym idzie, dały impuls do intensywnych poszukiwań skutecznych metod prewencji i leczenia. Niniejszy artykuł ma na celu przybliżenie dostępnych obecnie interwencji terapeutycznych, ich skuteczności oraz wpływu na dalszy przebieg choroby.

EN

Nonalcoholic fatty liver disease (NAFLD) is a condition comprising a broad spectrum of pathophysiological changes (abnormalities) ranging from simple fatty liver (SFL) through nonalcoholic steatohepatitis (NASH) to hepatic cirrhosis with all its possible complications, hepatocellular carcinoma (HCC) including. Although the concept of NAFLD has been present in the literature for over 30 years, for most of that time it used to be considered a benign condition with little clinical importance. It has only been the research of recent years that focused on long term medical and social consequences of NAFLD. This has given an incentive to search further for effective methods of NAFLD prevention and treatment. The aim of the present paper is to present currently available therapeutic interventions, their effectiveness and the influence on the history of the disease.

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2011
• Tom: 38
• Numer: 4
• Opis fizyczny: s.269-283,tab.,bibliogr.

Twórcy

autor

Kolakowski M.

• Zespół Oddziałów Chorób Wewnętrznych i Gastroenterologii, Mazowiecki Szpital Wojewódzki w Warszawie Sp. z o.o., Warszawa

autor

Kukla M.

autor

Jarosz M.

Bibliografia

• 1. Ludwig J., Viggiano TR., McGill DB. i wsp., Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease, Mayo Clin Proc 1980, 55, 434-438.-
• 2. Brunt EM., Nonalcoholic steatohepatitis, Semin Liver Dis 2004, 24, 1, 3-20.-
• 3. Neuschwander-Tetri BA., Caldwell SH., Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference, Hepatology, 2003, 37, 5, 1202-1219.-
• 4. Bugianesi E., Leone N., Vanni E., i wsp., Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma, Gastroentrology, 2002, 123, 1, 134-140.-
• 5. Browning J., Szczepaniak L., Dobbins R. i wsp., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, 2004, 40, 1387-1395.-
• 6. Machado M., Marques-Vidal P., Cortez-Pinto H., Hepatic histology in obese patients undergoing bariatric surgery, J. Hepatol. 2006, 45, 4, 600-606.-
• 7. Kukla M., Zwirska-Korczala K., Gabriel A. i wsp., Liver tissue alterations in morbidly obese patients undergoing bariatric surgery, Exp Clin Hepatol 2007, 3, 3, 12-18.-
• 8. Jarosz M., Rychlik E., Epidemia otyłości - jaka przyszłość nas czeka?, Gastroenterologia Polska, 2010, 17, 1, 47-52.-
• 9. Jarosz M., Rychlik E.: Overweight and obesity among adults in Poland 1983-2005, Adv. Med. Sci., 2008, 53, 2, 158-166.-
• 10. Donnelly K., Smith, C., Schwarzenberg i wsp., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J. Clin. Invest. 2005, 115, 5, 1139-1142.-
• 11. Weisberg S., McCann D., Desai M., i wsp., Obesity is associated with macrophage accumulation in adipose tissue, J. Clin. Invest. 2003, 112, 1796-1808.-
• 12. Xu A., Wang Y., Keshaw H. i wsp., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J. Clin. Invest. 2003, 112, 91-100.-
• 13. Tacikowski T., Dzieniszewski J., Ciok J. i wsp., Niealkoholowa choroba stłuszczeniowa wątroby, Gastroenterologia Polska 2004, 11, 3, 271-278.-
• 14. Hui J.M., Sud A., Farrell G.C. i wsp., Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression, Gastroneterology 2003, 125, 6, 1695-1704.-
• 15. Das K., Kar P., Update article: Non-alcoholic steatohepatitis, JAPI 2005, 53, 195-199.-
• 16. Kukla M., Zwirska-Korczala K., Gabriel A. i wsp,. Chemerin, vaspin and insulin resistance in chronic hepatitis C, J. Viral Hepat. 2010, 17, 9, 661-667.-
• 17. Gabriel A., Kukla M., Ziółkowski A., Histopathological features and current scoring systems for semiquantitative assessment of nonalcoholic fatty liver disease, Exp. Clin. Hep. 2008, 4, 1, RA48-54.-
• 18. Joy D., Thava V., Scott B,. Diagnosis of fatty liver disease: is biopsy necessary?, Eur. J. Gastroenterol. Hepatol. 2003, 15, 5, 539-543.-
• 19. Ratziu V., Massard J., Charlotte F. i wsp., Diagnostic value of biochemical markers (FibroTest- FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease, BMC Gastroenterol. 2006, 14, 6, 6-34.-
• 20. Angulo .P, Hui J., Marchesini G. i wsp., The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology 2007, 45, 4, 846-854.-
• 21. Harrison S., Oliver D., Arnold H. i wsp., Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease, Gut 2008, 57, 10, 1441-1447.-
• 22. Huang M., Greenson J., Chao C. i wsp., One-year intesnse nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study, Am. J. Gastroenterol. 2005, 100, 5, 1072-1081.-
• 23. De Luis D., Aller R., Izaola O. i wsp., Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance, Diabetes. Res. Clin. Pract., 2008, 79, 1, 74-78.-
• 24. Ryan M., Abbasi F., Lamendola C. i wsp., Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults, Diabetes Care, 2007, 30, 5, 1075-1080.-
• 25. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R. i wsp., Long term nutritional intake and the risk for nonalcoholic fatty liver disease (NAFLD): a population based study, J. Hepatol. 2008, 47, 5, 711-717.-
• 26. Sabuncu T., Nazligul Y., Karaoglanoglu M. i wsp., The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with nonalcoholic steatohepatitis, Rom. J. Gastroenterol. 2003, 12, 3, 189-192.-
• 27. Gary-Bobo M., Elachouri G., Gallas J. i wsp., Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats, Hepatology 2007, 46, 1, 122-129.-
• 28. Tushuizen M., Bunck M., Pouwels .P i wsp., Incretin mimetics as a novel therapeutic option for hepatic steatosis, Liver Int 2006, 26, 8, 1015-1017.-
• 29. Mattar S., Velcu L., Rabinovitz M. i wsp., Surgically induced weight loss significantly improved nonalcoholic fatty liver disease and the metabolic syndrome, Ann. Surg., 2005, 242, 4, 610-620.-
• 30. Dixon J., Bhathal P., O´Brien P., Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement, Obes. Surg., 2006, 16, 10, 1278-1286.-
• 31. Sanyal A., Mofrad P., Contos M. i wsp., A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis, Clin. Gastroenterol. Hepatol., 2004, 2, 12, 1107-1115.-
• 32. Belfort R., Harrison S., Brown K. i wsp., A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N. Engl. J. Med., 2007, 355, 22, 2297-2307.-
• 33. Aithal G., Thomas J., Kaye P. i wsp., Randomized, placebo controlled trial of pioglitazone in non-diabetic subjects with nonalcoholic steatohepatitis (NASH), Gastroenterology, 2008, 135, 4, 1176-1184.-
• 34. Ratziu V., Giral P., Jacqueminet S. i wsp., Rosiglitazone for nonalcoholic steatohepatitis: Oneyear results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial, Gastroenterology, 2008, 135, 1, 100-110.-
• 35. Uygun A., Kadayifci A., Isik A. i wsp., Metformin in the treatment of patients with non-alcoholic steatohepatitis, Aliment. Pharmacol. Ther., 2004, 19, 5, 537-544.-
• 36. Gomez-Dominguez E., Gisbert J., Moreno-Monteagudo J. i wsp., A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients, Aliment. Pharmacol. Ther. 2006, 23, 11, 698-699.-
• 37. Lewis J., Mortensen M., Zweig S. i wsp., Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebocontrolled, multicenter trial, Hepatology, 2007, 46, 5, 1453-1463.
• 38. Deushi M., Nomura M., Kawakami A. i wsp., Ezetimibe improves liver steatosis and insulin resistance in obese model of metabolic syndrome, FEBS Lett. 2007, 581, 29, 5664-5670.-
• 39. Araki T., Kitaoka H., Antioxidative properties of probucol estimated by the reactivity with superoxide and by electrochemical oxidation, Chem. Pharm. Bull. 2001, 49, 8, 943-947.-
• 40. Merat S., Malekzadeh R., Sohrabi M. i wsp., Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study, J. Hepatol. 2003, 38, 4, 414-418.-
• 41. Merat S., Aduli M., Kazemi R. i wsp., Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol, Dig. Dis. Sci., 2008, 53, 8, 2246-2250.-
• 42. Basaranoglu M., Acbay O., Sonsuz A. i wsp., A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis (letter), J. Hepatol. 1999, 31, 2, 384.-
• 43. Yakaryilmaz F., Guliter S., Savas B. i wsp,. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-( alpha) expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study, Intern. Med. J., 2007, 37, 4, 229-235.-
• 44. Harrison S., Torgerson S., Hayashi P. i wsp., Vitamin E and vitamin C improves fibrosis in patients with nonalcoholic steatohepatitis, Am. J. Gastroenterol. 2003, 98, 11, 2485-2490.-
• 45. Federico A., Trappoliere M., Tuccillo C. i wsp., A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations, Gut, 2006, 55, 6, 901-902.-
• 46. Miller E., Pastor-Barriuso R., Dalal D. i wsp,. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality, Ann. Intern. Med., 2005, 142, 1, 37-46.-
• 47. Craig S.A., Betaine in human nutrition, Am. J. Clin. Nutr., 2004, 80, 3, 539-549.-
• 48. Abdelmalek M., Angulo P., Jorgensen R. i wsp., Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study, Am. J. Gastroenterol., 2001, 96, 9, 2711-2717.-
• 49. Miglio F., Rovati L., Santoro A. i wsp., Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study, Arzneimittelforschung, 2000, 50, 8, 722-727.-
• 50. Santos V., Lanzoni V., Szenjnfeld J. i wsp., A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid, Brazilian J. Med. Bio. Res., 2003, 36, 6, 723-729.-
• 51. Lindor K., Kowdley K., Heathcote E. i wsp., Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology, 2004, 39, 3, 770-778.-
• 52. Dufour J., Oneta C., Gonvers J. i wsp., Randomized placebo-controlled trial of ursodeoxycholic acid with vitamine E in nonalcoholic steatohepatitis, Clin. Gastroenterol. Hepatol., 2006, 4, 12, 1537-1543.-
• 53. Adams L., Zein C., Angulo P. i wsp., A pilot trial of pentoxifylline in nonalcoholic steatohepatitis, Am. J. Gastroenterol., 2004, 99, 12, 2365-2368.-
• 54. Satapathy S., Sakhuja P., Malhotra V. i wsp., Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroin-lammation in patients with non-alcoholic steatohepatitis, J. Gastroenterol. Hepatol., 2007, 22, 5, 634-638.-
• 55. Baumgardner J.N., Shankar K., Hennings L. i wsp., N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis, J. Nutr., 2008, 138, 10, 1872-1879.-
• 56. Pamuk G.E., Sonsuz A., N-acetylcysteine in the treatment of non-alcoholic steatohepatitis, J. Gastroenterol Hepatol., 2003, 18, 10, 1220-1221.-
• 57. Gülbahar O., Karasu Z.A., Ersöz G., Treatment non-alcoholic steatohepatitis with N-acetylcysteine, Gastroenterology, 2000, 118, A1444.-
• 58. Toblli J., Munoz M., Cao G. i wsp., ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats, Obesity, 2008, 16, 4, 770-776.-
• 59. Rinella M., Elias M., Smolak R. i wsp., Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet, J. Lipid. Res., 2008, 49, 5, 1068-1076.-
• 60. Charatcharoenwitthaya P., Levy C., Angulo P., Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis, Liver Int., 2007, 27, 2, 220-226.-
• 61. Dunn W., Xu R., Schwimmer J. i wsp., Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease, Hepatology, 2008, 47, 6, 1947-1954.-
• 62. Lirussi F., Mastropasqua E., Orando S. i wsp., Probiotics for nonalcoholic fatty liver disease and/or steatohepatitis, Cochrane Database Syst. Rev., 2007, 24, 1, CD005165.-
• 63. Loguercio C., Federico A., Tuccillo C. i wsp., Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases, J Clin Gastroenterol, 2005, 39, 6, 540-543.-
• 64. Solga S.F., Buckley G., Clark J.M. i wsp., The effect of a probiotic on hepatic steatosis, J. Clin. Gastroenterol., 2008, 42, 10, 1117-1119.

Uwagi

Rekord w opracowaniu